Trade Bristol Myers ^BMY

Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)

Is Bristol Myers Squibb (BMY) Price Near US$60 Supported By Cash Flow And Earnings Models

Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry

Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation

Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players

Retirement Systems of Alabama Boosts Position in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Purchased by Retirement Systems of Alabama - Daily Political

MOAT ETF Is Down 7% in 2026. Here Is the Macro Signal That Changes Everything

Advanced Melanoma Markets and Companies 2026-2030: Cumulative Revenue to Grow by $1.87 Billion

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Paranasal Sinus Cancer Markets and Competition Outlook 2026-2030 - Precision Oncology, Minimally Invasive Surgeries, and Expanded Cancer Care Models Drive Revenue Growth

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Non-Small Cell Lung Cancer (NSCLC) Global Market Trends and Regional Growth Insights 2026-2030: Rapid Adoption of Targeted Therapies and Immunotherapy Fuels Market Expansion, Reaching $70.8 Billion by 2030

Exchange Traded Concepts LLC Decreases Stock Holdings in Bristol Myers Squibb Company $BMY

1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm

Northwest Wealth Management LLC Makes New $689,000 Investment in Bristol Myers Squibb Company $BMY - Stock Observer

Bristol-Myers Squibb Gets FDA Approval for Hodgkin's Lymphoma Treatment

15 Large-cap Stocks with Highest Dividends

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now?

Cobenfy Phase 4 Data May Reframe Bristol Myers Squibb Valuation Story

Trial met its primary endpoint, demonstrating clinically mea

Precision Medicine Breakthrough: Mavacamten Markedly Reduces Heart Obstruction in Teens with Hypertrophic Cardiomyopathy

Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) | Morningstar

Bristol Myers announces data from Phase 4 trial of Cobenfy | Markets Insider

Bristol-Myers Squibb Company (NYSE:BMY) Looks Like A Good Stock, And It's Going Ex-Dividend Soon

A Look At Bristol Myers Squibb (BMY) Valuation As Growth Portfolio Outperforms Recent GAAP Loss

Bristol-Myers Squibb (BMY) Faces Mixed Analyst Sentiment Despite Strong Momentum in Healthcare Industry

Wedge Capital Management L L P NC Decreases Stake in Bristol Myers Squibb Company $BMY

Top Pharmaceutical Stocks To Watch Today - March 25th - Markets Daily

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026

Nepsis Inc. Acquires 90,852 Shares of Bristol Myers Squibb Company $BMY

High treatment completion and no discontinuations due to lac

Top 10 Stocks to Invest in For Financial Stability

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride) | Morningstar

Bristol Myers Squibb Company $BMY Shares Sold by Wedge Capital Management L L P NC - Stock Observer

Kaufman Rossin Wealth LLC Invests $629,000 in Bristol Myers Squibb Company $BMY - Stock Observer

ET Pharma: Pharma News | Latest Pharma Sector Information and Updates

Jim Cramer on Bristol-Myers Squibb: "The Stock's Recent Pullbacks Have Represented Terrific Buying Opportunities"

Anti-Cancer MAbS Market Report 2026-2030 Featuring Strategic Analysis of Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, Roche, GlaxoSmithKline and Other Key Players

Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth

A Look At Bristol Myers Squibb (BMY) Valuation As Shares Show Mixed Recent Returns

A New Era in Schizophrenia Care: National Council for Menta

Global X Japan Co. Ltd. Raises Stock Position in Bristol Myers Squibb Company $BMY - Stock Observer

BMS-986482 induces pan-IKZF degradation and robust tumor growth inhibition | BioWorld

Metastatic Triple-Negative Breast Cancer Market: Strong Growth Potential Across APAC Through 2036, Driven by Innovation and Rising Disease Burden | DelveInsight

Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb

Expanded Opdivo Use and New Camzyos Data Could Be A Game Changer For Bristol Myers Squibb (BMY)

Bristol Myers Squibb Company $BMY Position Raised by Czech National Bank

Erste Group Bank Has Positive Outlook of BMY FY2026 Earnings - Daily Political

Moody National Bank Trust Division Has $1.32 Million Stake in Bristol Myers Squibb Company $BMY - Daily Political

Why Bristol-Myers Squibb (BMY) Stock Is Up Today

SCHD Annual Reconstitution: Here's What This Dividend ETF Looks Like Now - AOL

Top Pharmaceutical Stocks To Watch Today - March 25th - Daily Political

Bristol Myers Squibb Leans On AI ALS Pact As Valuation Question Persists

Pensionfund Sabic Takes $1.85 Million Position in Bristol Myers Squibb Company $BMY - Daily Political

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial

Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

Procyon Advisors LLC Sells 20,349 Shares of Bristol Myers Squibb Company $BMY - Markets Daily

Colgate-Palmolive Board And Asia Leadership Shifts Spark Value Questions

What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.

E. Ohman J or Asset Management AB Buys 46,000 Shares of Bristol Myers Squibb Company $BMY

Insitro and Bristol Myers Squibb expand ALS collaboration | BioWorld

Enhanced dynamic risk stratification of smoldering multiple myeloma

Wealth Enhancement Advisory Services LLC Purchases 318,898 Shares of Bristol Myers Squibb Company $BMY

Replimune's Oncolytic Viral Therapy For Melanoma Faces Second Shot At FDA Approval

Opdivo's New cHL Approvals Reframe Bristol-Myers Squibb Growth Story

NorthCrest Asset Manangement LLC Has $24.56 Million Stock Position in Bristol Myers Squibb Company $BMY - Daily Political

A Look At Bristol Myers Squibb (BMY) Valuation As Recent Results Shape Growth And Cost Outlook

20,156 Shares in Bristol Myers Squibb Company $BMY Purchased by MFG Wealth Management Inc. - Stock Observer

Bristol Myers Squibb Company $BMY Shares Acquired by TruWealth Advisors LLC - Daily Political

Bristol Myers Squibb Gets Expanded Opdivo Approval in U.S., Europe | Morningstar

In the U.S., FDA approval establishes Opdivo in combination

Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab) | Morningstar

Union Bancaire Privee UBP SA Boosts Stake in Bristol Myers Squibb Company $BMY

Miller Global Investments LLC Invests $1.11 Million in Bristol Myers Squibb Company $BMY

Bristol Myers Squibb Company $BMY Shares Purchased by Mirabella Financial Services LLP

Union Bancaire Privee UBP SA Boosts Position in Bristol Myers Squibb Company $BMY - Daily Political

20,650 Shares in Bristol Myers Squibb Company $BMY Bought by Miller Global Investments LLC - Daily Political

Bristol Myers Squibb Kidney Cancer Trial Tests Valuation And Pipeline Depth

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium

International testing and refinement of AI algorithms predicting acute leukemia subtypes from routine laboratory data

These 3 Stocks Trigger Bearish Signals but 2 Offer Hidden Opportunity

Bristol Myers Squibb Tests New Protein Degradation Cancer Drug In Humans

12,955 Shares in Bristol Myers Squibb Company $BMY Purchased by Investment Research Partners LLC - Daily Political

How Mezigdomide Trial Progress And Sotyktu Expansion At Bristol Myers Squibb (BMY) Has Changed Its Investment Story

WBI Investments LLC Has $2.70 Million Stock Holdings in Bristol Myers Squibb Company $BMY

20 Years on Wall Street Taught Me: Big Dividend Healthcare Stocks Never Go Out of Style

Danske Bank A S Makes New $71.59 Million Investment in Bristol Myers Squibb Company $BMY